Highland Capital Management 13F: New $2.9M Stake in Amgen (AMGN)
Key Points
- Highland Capital Management took a new position in Amgen Inc. with 6,993 shares worth about $2.95 million, as reported in its latest Form 13F filing.
- Amgen's shares recently traded around $444.71, slightly above the event-day close of $444.63, and are 54.4% above their 52-week low of $288.00.
- The stock has a market capitalization of approximately $240.4 billion and a P/E ratio of about 27.6, indicating strong market interest.
Get Amgen text alerts
We text you when insiders, Congress, analysts or big funds move on $AMGN.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Amgen Inc. alert may contain errors. Disclosures
Highland Capital Management took a new position in Amgen Inc. (AMGN) by acquiring 6,993 shares valued at $2,947,619 in a filing on October 26, 2026. This information comes from the fund's latest Form 13F filing with the SEC.
AMGN
Amgen Inc.
Where Amgen Fits in Highland Capital Management's Portfolio
Amgen represents 0.35% of Highland's reported 13F portfolio, ranking 29th among its 415 positions. This new stake adds significant value, as the fund has not held shares in Amgen before.
Other Institutional Activity in Amgen
Nisa Investment Advisors recently increased its stake in Amgen by 8,294 shares, bringing its total to 167,256 shares valued at about $70.5 million. Meanwhile, E. Ohman J:or Asset Management reduced its holdings by 5,983 shares, ending with 13,532 shares worth approximately $5.7 million.
Amgen Inc. Stock Up 1.2%
Amgen's shares recently traded around $444.71, which is about equal to the event-day close of $444.63 on October 26, 2026. This price is 54.4% above the 52-week low of $288.00 but 1.4% below the 52-week high of $450.98.
Recent Earnings
For the trailing twelve months, Amgen reported revenue of approximately $38.1 billion and an EPS of $16.10. The company is scheduled to announce its next earnings on November 3, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
2 target cuts vs 1 raises.
-
EPS & revenue
EPS beat estimates by 6.1%. Revenue missed estimates by 1.5%.
-
Profit surprise
EBITDA missed by 45 percent. Operating income missed by 28 percent.
-
Pre-earnings setup
Expectations were about average.
-
Analyst signal
1 target raise, 2 target cuts.
-
Earnings quality
Gross margin up 4.6 points. Operating margin up 16.5 points. Positive free cash flow.
Earnings Call Summary
Amgen had a strong first quarter with earnings per share of 5.15 dollars beating expectations of 4.73 dollars. Six key medicines grew sales by 24 percent year over year and now make up 70 percent of total sales. The obesity drug Meritide is advancing well in late-stage testing with new studies showing better tolerance when patients take it less frequently, potentially every eight to twelve weeks instead of weekly injections.
Guidance Amgen raised its 2026 outlook to revenue between 37.1 billion and 38.5 billion dollars, and earnings per share between 21.70 and 23.10 dollars. The company expects its fast-growing medicines like Repatha and Evenity to offset patent losses. Management said capital spending will remain at about 2.6 billion dollars to scale manufacturing for new drug launches.
Clearly negative report. The company missed important expectations and likely triggers downward revisions.
Insider Buying and Selling at Amgen Inc.
Several insiders sold shares earlier this year, with Officer Nancy A. Grygiel selling 2,970 shares at an average price of $402.16 on August 6, 2026, totaling about $1.19 million. Officer Derek Miller sold 3,890 shares at an average price of $402.54, worth about $1.57 million on the same day.
Analysts Set New Price Targets
On October 12, 2026, BMO Capital maintained a "Market Perform" rating with a price target of $415.00. Oppenheimer also maintained an "Outperform" rating, raising its target to $480.00 on October 23, 2026. The consensus among analysts is to hold, with a mean target price of $397.32.
About Amgen
Amgen Inc. is a biotechnology company that discovers, develops, manufactures, and delivers human therapeutics worldwide. This new position by Highland Capital Management could indicate a growing interest in Amgen's innovative therapies in the healthcare sector.
Bottom Line
Investors should watch for Amgen's upcoming earnings report on November 3, 2026, as well as further filings from Highland Capital Management. This new position reflects growing confidence in Amgen's future performance.
Related Filing Alerts
Source: Highland Capital Management's 13F filing on $AMGN (Oct 26, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts